

**ACTION:** Notice.

**SUMMARY:** Notice is hereby given that the U.S. International Trade Commission has issued a limited exclusion order (“LEO”) against infringing products manufactured and/or imported by or on behalf of Proton Sports Inc. (“Proton”) of Scottsdale, Arizona, and a cease and desist order (“CDO”) against Proton. The investigation is terminated.

**FOR FURTHER INFORMATION CONTACT:**

Clint Gerdine, Office of the General Counsel, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone (202) 708–2310. Copies of non-confidential documents filed in connection with this investigation may be viewed on the Commission’s electronic docket system (“EDIS”) at <https://edis.usitc.gov>. For help accessing EDIS, please email [EDIS3Help@usitc.gov](mailto:EDIS3Help@usitc.gov). General information concerning the Commission may also be obtained by accessing its internet server at <https://www.usitc.gov>. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission’s TDD terminal, telephone (202) 205–1810.

**SUPPLEMENTARY INFORMATION:** The Commission instituted this investigation on November 2, 2021, based on a complaint filed and supplemented by Easton Diamond Sports, LLC (“Easton”) of Thousand Oaks, California. 86 FR 60468–469 (Nov. 2, 2021). The complaint alleges a violation of section 337 of the Tariff Act, as amended, 19 U.S.C. 1337, based on the importation, sale for importation, or sale in the United States after importation of certain composite baseball and softball bats and components thereof by reason of infringement of one or more asserted claims of U.S. Patent No. 6,997,826 (“the ‘826 patent”). *Id.* The complaint further alleges the existence of a domestic industry. *Id.* The Commission’s notice of investigation (“NOI”) names Proton; Juno Athletics LLC (“Juno”) of Aventura, Florida; and Monsta Athletics LLC (“Monsta”) of Calimesa, California as respondents. *Id.* at 60469. The Office of Unfair Import Investigations is not a party to this investigation. *Id.*

On January 25, 2022, the Commission amended the complaint and NOI to add TianChang Zhengmu Aluminum Technology Co., Ltd. (“TZA”) of Tianching City, China as a respondent. *See* Order No. 8 (Dec. 28, 2021), *unreviewed by* Comm’n Notice (Jan. 25, 2022). On February 16, 2022, the Commission terminated TZA from the investigation based on withdrawal of

the complaint. *See* Order No. 11 (Jan. 28, 2022), *unreviewed by* Comm’n Notice (Feb. 16, 2022).

On April 12, 2022, the Commission found Proton in default for failure to respond to the complaint and NOI and for failure to respond to these order to show cause why it should not be found in default for failing to respond to the complaint and NOI (Order No. 7). *See* Order No. 13 (March 30, 2022), *unreviewed by* Comm’n Notice (April 12, 2022).

On July 25, 2022, the Commission terminated respondent Monsta from the investigation based on withdrawal of the complaint. *See* Order No. 21 (June 27, 2022), *unreviewed by* Comm’n Notice (July 25, 2022).

On July 11, 2022, the currently presiding ALJ issued Order No. 23, which terminated the investigation as to the last participating respondent, Juno, based on a settlement agreement. Easton did not request issuance of a general exclusion order. The Commission determined not to review Order No. 23 and requested written submissions on the issues of remedy, the public interest, and bonding with respect to Proton. 87 FR 48690–91 (Aug. 10, 2022).

On August 26, 2022, Easton submitted briefing responsive to the Commission’s request. Easton argued that the Commission should issue an LEO directed to Proton’s infringing products and a CDO directed to Proton. No other submissions were received.

When the conditions in section 337(g)(1)(A)–(E) (19 U.S.C. 1337(g)(1)(A)–(E)) have been satisfied, section 337(g)(1) and Commission Rule 210.16(c) (19 CFR 210.16(c)) direct the Commission, upon request, to issue a limited exclusion order or a cease and desist order or both against a respondent found in default, based on the allegations regarding a violation of section 337 in the Complaint, which are presumed to be true, unless after consideration of the public interest factors in section 337(g)(1), it finds that such relief should not issue.

Having reviewed the record in the investigation, including written submissions from Easton, the Commission has determined pursuant to section 337(g)(1) that the appropriate remedy in this investigation is an LEO directed to the defaulting respondent prohibiting the unlicensed entry of composite baseball and softball bats and components thereof that infringe one or more of claims 1–5, 9–12, 14–15, and 18–19 of the ‘826 patent, and that are manufactured abroad by or on behalf of, or imported by or on behalf of Proton, or any of its affiliated companies, parents, subsidiaries, or other related

business entities, or their successors or assigns.

The Commission has also determined to issue a CDO prohibiting Proton from conducting any of the following activities in the United States: importing, selling, marketing, advertising, distributing, offering for sale, transferring (except for exportation), and soliciting U.S. agents or distributors for composite baseball and softball bats and components thereof that infringe one or more of claims 1–5, 9–12, 14–15, and 18–19 of the ‘826 patent.

The Commission has further determined that the public interest factors enumerated in section 337(g)(1) do not preclude issuance of the LEO or CDO. Finally, the Commission has determined that a bond in the amount of 100 percent of the entered value of the covered products is required during the period of Presidential review (19 U.S.C. 1337(j)). The Commission’s order was delivered to the President and to the United States Trade Representative on the day of its issuance.

The Commission voted to approve this determination on November 1, 2022.

The authority for the Commission’s determinations is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in part 210 of the Commission’s Rules of Practice and Procedure (19 CFR part 210).

By order of the Commission.

Issued: November 1, 2022.

**Katherine Hiner,**

*Acting Secretary to the Commission.*

[FR Doc. 2022–24053 Filed 11–3–22; 8:45 am]

**BILLING CODE 7020–02–P**

**DEPARTMENT OF JUSTICE****Drug Enforcement Administration**

[Docket No. DEA–1099]

**Bulk Manufacturer of Controlled Substances Application: Organix Chemistry Solutions LLC**

**AGENCY:** Drug Enforcement Administration, Justice.

**ACTION:** Notice of application.

**SUMMARY:** Organix Chemistry Solutions LLC, has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to **SUPPLEMENTARY INFORMATION** listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit

electronic comments on or objections to the issuance of the proposed registration on or before January 3, 2023. Such persons may also file a written request for a hearing on the application on or before January 3, 2023.

**ADDRESSES:** The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment

field on the web page or attach a file for lengthier comments. Please go to <https://www.regulations.gov> and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on <https://www.regulations.gov>. If you have received a Comment Tracking Number, your comment has been

successfully submitted and there is no need to resubmit the same comment.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.33(a), this is notice that on September 26, 2022, Organix Chemistry Solutions LLC, 240 Salem Street, Woburn, Massachusetts 01801–2029, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Gamma Hydroxybutyric Acid .....	2010	I
Lysergic acid diethylamide .....	7315	I
Marihuana .....	7360	I
Tetrahydrocannabinols .....	7370	I
Mescaline .....	7381	I
3,4,5- Trimethoxyamphetamine .....	7390	I
4-Bromo-2,5-dimethoxyphenethylamine .....	7392	I
3,4-Methylenedioxyamphetamine .....	7400	I
3,4-Methylenedioxymethamphetamine .....	7405	I
5-Methoxy-N–N-dimethyltryptamine .....	7431	I
Alpha-Methyltryptamine .....	7432	I
Bufotenine .....	7433	I
Diethyltryptamine .....	7434	I
Dimethyltryptamine .....	7435	I
Psilocybin .....	7437	I
Psilocyn .....	7438	I
2-(2,5-Dimethoxy-4-methylphenyl) ethanamine (2C–D) .....	7508	I
2-(2,5-Dimethoxyphenyl) ethanamine (2C–H) .....	7517	I
2-(4-Iodo-2,5-dimethoxyphenyl) ethanamine (2C–I) .....	7518	I
Heroin .....	9200	I
Morphine .....	9300	II

The company plans to synthesize the above listed controlled substances for distribution to its customers. In reference to drug codes 7360 (Marihuana), and 7370 (Tetrahydrocannabinols), the company plans to bulk manufacture these drugs as synthetic. No other activities for these drug codes are authorized for this registration.

**Kristi O’Malley,**  
*Assistant Administrator.*  
 [FR Doc. 2022–24103 Filed 11–3–22; 8:45 am]  
**BILLING CODE P**

**DEPARTMENT OF LABOR**

**Employee Benefits Security Administration**

**214th Meeting of the Advisory Council on Employee Welfare and Pension Benefit Plans; Notice of Meeting**

Pursuant to the authority contained in Section 512 of the Employee Retirement Income Security Act of 1974 (ERISA), 29 U.S.C. 1142, the 214th open meeting of the Advisory Council on Employee Welfare and Pension Benefit Plans (also

known as the ERISA Advisory Council) will be held on December 8–9, 2022.

On Thursday, December 8, 2022, the meeting will begin at 1 p.m. and end at approximately 4:30 p.m. (ET). On Friday, December 9, 2022, the meeting will begin at 8:30 a.m. and end at approximately 3 p.m. (ET), with a one-hour break for lunch. The meeting will take place at the U.S. Department of Labor, 200 Constitution Avenue NW, Room C5515—1A/1B, Washington, DC 20210. The meeting will also be accessible via teleconference and some participants, as well as members of the public, may elect to attend virtually. Instructions for public teleconference access will be available on the ERISA Advisory Council’s web page at <https://www.dol.gov/agencies/ebsa/about-ebsa/about-us/erisa-advisory-council> approximately one week prior to the meeting.

The purpose of the open meeting is for the members of the ERISA Advisory Council to finalize their observations and recommendations on the issues they studied in 2022, present their observations and recommendations to the Department of Labor, and receive an update from leadership of the Employee

Benefits Security Administration (EBSA).

The issues studied by the ERISA Advisory Council in 2022 are: (1) Cybersecurity Issues Affecting Health Benefit Plans, and (2) Cybersecurity Insurance and Employee Benefit Plans. Descriptions of these issues are available on the ERISA Advisory Council’s web page at <https://www.dol.gov/agencies/ebsa/about-ebsa/about-us/erisa-advisory-council>.

Organizations or members of the public wishing to submit a written statement may do so on or before Thursday, December 1, 2022, to Christine Donahue, Executive Secretary, ERISA Advisory Council. Statements should be transmitted electronically as an email attachment in text or pdf format to [donahue.christine@dol.gov](mailto:donahue.christine@dol.gov). Statements transmitted electronically that are included in the body of the email will not be accepted. Relevant statements received on or before Thursday, December 1, 2022, will be included in the record of the meeting and made available through the EBSA Public Disclosure Room. No deletions, modifications, or redactions will be made to the statements received as they are public records.